The Sixth Joint Task Force of the European Society of Cardiology (ESC) and Other Societies on Cardiovascular Disease Prevention in Clinical Practice Guidelines have been published in 2016: greater emphasis has been placed on a populationbased approach, on disease-specific interventions and on female-specific conditions, younger individuals and ethnic minorities. The ESC guidelines underscore that a lifetime approach to cardiovascular risk is important as both risk and prevention are dynamic and continuous. The guidelines can assist healthcare professionals, patients, and are valuable for the healthcare system but implementation of secondary cardiovascular disease prevention is far from optimal. Although there is no single way to ensure the use of guidelines in practice, multifaceted interventions based on known barriers are most appropriate. Essential components for implementation are: (a) taking action; (b) strengthening capacity; (c) evaluating impact; (d) advancing policy; and (e) engaging in regional and global partnerships. The strategy depends on a balanced investment in all available intervention approaches, from policy and environmental changes designed to prevent risk factors to assurance of quality care for individuals with cardiovascular disease. Our greatest challenges represent our greatest opportunities.
Every 29 seconds, someone will experience a coronary event in the United States, and every 60 seconds, someone will die from such an event:
1 early death, disability, personal and family disruption, loss of income (more than US$142 billion for 2003), and medical care expenditures (more than US$209 billion) are important indicators for public health strategies and expenditure. 1 The epidemic of cardiovascular disease (CVD) is expected to continue, with an increasing burden and widening disparities, unless unprecedented public health efforts are mounted to arrest and reverse it. The effective reduction of CVD mortality is based on three key points: 2 surveillance, prevention and equitable healthcare for individuals with CVD. Therefore, CVD prevention is a public health priority; however, although many of the risk factors for recurrent CVD episodes are to a certain extent preventable and/or modifiable via lifestyle choices, CVD prevention is little implemented, and governments devote a small proportion of health spending to the prevention of diseases. 3 
The knowledge
The Sixth Joint Task Force of the European Society of Cardiology (ESC) and Other Societies on
Cardiovascular Disease Prevention in Clinical Practice
Guidelines have been published in 2016. 4 Compared with the previous guidelines, greater emphasis has been placed on a population-based approach, on disease-specific interventions and on female-specific conditions, younger individuals and ethnic minorities. The ESC guidelines underscore that a lifetime approach to cardiovascular risk is important because both risk and prevention are dynamic and continuous, and 'to do and not to do' messages have been provided (Tables 1 and 2 ). As regards CVD prevention costeffectiveness, as it depends on parameters such as the target population's age, overall population risk of CVD and cost of interventions, 4 results obtained in one country may not be valid in another, and changes such as the introduction of generic drugs can considerably change cost-effectiveness. Secondary prevention should be started as soon as possible, 6 and the commitment of acute physicians is recommended. Prevention strategies in CVD patients, including lifestyle changes, risk factor management and pharmacological optimisation should be provided after an acute event, before hospital discharge, 7, 8 and the failure to do so may suggest that these measure are valueless. 9, 10 Hence, an appropriate discharge phase 11 should include the identification of post-discharge patients' needs, medications reconciliation, a patient/ family education process with continual reinforcement throughout the organisation of daily re-demonstration/ teach-back by the patient. For high-risk CVD patients, specialised prevention programmes are recommended, delivered as inpatient or outpatient cardiac rehabilitation (CR) programmes. CR is a comprehensive programme involving exercise training, risk factor modification, education and psychological support, 12 and although core components and goals of CR have been standardised, 12, 13 the structure, length and type of programme offered differs widely, according to countries' administrative rules, payments and availability. 4 Nonetheless, in low to moderate risk patients with heart failure, or in those post-myocardial infarction or revascularisation, exercise-based CR decreased hospital admissions and improved health-related quality of life compared with usual care, and may reduce mortality in the longer term.
14 Thus more research is desirable to determine the optimal CR intervention, and new models of CR delivery are needed to improve the enrollment and completion of CR, because the current capacity of the existing CR programme is only sufficient enough to enroll approximately 50% of eligible patients. 4 In conclusion, CVD prevention is a coordinated set of actions, at the population level or targeted at an individual, that are aimed at eliminating or minimising the impact of CVDs and their related disabilities. Table 2 . Gaps of evidence in risk factors interventions and preventive therapy in the recent ESC guidelines (see also legend).
Behaviour change
There is limited evidence to determine which interventions are most effective in specific groups.
Psychosocial factors
Evidence that treatment of clinically significant depression and anxiety alone will prevent CVD and improve outcomes is inconclusive. Sedentary behaviour and PA
The lower and upper limit of aerobic PA intensity, duration and frequency to exert a beneficial effect is unknown. The effectiveness of PA monitoring versus simple counselling to optimise the motivation of patients to adhere to active lifestyle is unknown. The role and sustainability of modern technology for motivating people to undertake more PA has not been established.
Smoking intervention
More efficient, safe and cost-effective smoking cessation aids are required. Nutrition
The biggest challenge in dietary prevention of CVD is to develop more effective strategies to make people change their diet and to maintain that healthy diet and a normal weight. Research into the substances in foods that underlie the protective effects is ongoing. Body weight Implementation of effective strategies to achieve weight loss and maintain a long-term healthy weight is under examination. Identification of the relative roles of diet, exercise and behaviour modification in the management of overweight and obese people is to ascertain. The optimal level of BMI over the life course (at older ages and after a CV event) is unknown.
Lipid control
It is unknown if triglyceride or HDL-C values as a target for therapy, or whether Lp(a) lowering against background statin therapy can reduce the risk of CVD. It is unknown how to increase adoption of non-HDL-C and non-fasting samples in clinical practice, and whether functional foods and food supplements with a lipid-lowering effect can safely reduce the risk of CVD. Diabetes mellitus (type 2 and type 1)
Further studies are needed on metformin and GLP-1 receptor agonists in (subgroups of) patients with type 1 DM to determine whether they improve glycaemic control, aid in weight reduction and improve clinical outcomes. There is a need for a CVD risk score in type 1 DM to better guide initiation of preventative therapies in younger patients. Hypertension Drug treatment in white coat hypertension: it is unknown if and when drug treatment should be started in the high-normal BP range. The optimal office BP values for patients to achieve by treatment in different demographic and clinical conditions it is unknown yet. It is unknown whether the optimal out-of-office BP targets and treatment strategies provide an advantage over strategies based on conventional (office) BP control. Antiplatelet therapy Experience with the new antiplatelet drugs in patients with stable CAD is still limited and so is their use in combination with anticoagulant treatment. Adherence to medications There is limited evidence about which interventions for improving adherence to medication are the most effective and in whom. The effect of the polypill as a global strategy to reduce CVD remains uncertain.
See abbreviations for Table 1 . Statements from Piepoli et al.
The guidelines can assist healthcare professionals, patients, and are valuable for the healthcare system. The principal benefit of guidelines is to improve the quality of care to deliver, keeping abreast of new developments, through the provision of carefully evaluated summaries of available evidence. Clinical guidelines provide explicit recommendations about the diagnosis and treatment of specific diseases 3, 4 as well as potentially offering advice on a broad range of clinical problems and delivery of services (benefits for healthcare professionals). Moreover, clinical guidelines are often accompanied by 'consumer' versions that inform patients about what their clinicians should be doing and the services that they can expect. 15 Guidelines empower consumers of health services, enabling them to make informed choices, so enhancing patient participation in decision-making. Patients might influence public policy, 16 for example, by drawing attention to underserved populations or under-recognised health problems or by providing patients with a framework to evaluate the appropriateness of the care (benefits for patients). Finally, as clinical guidelines aim to enhance efficiency and optimise value for money, implementation in practice may reduce hospital outlays and facilitate the pursuit of cost containment. 17 Publicising adherence to guidelines has the potential to improve the public image of specific hospitals, which may promote goodwill and political support (benefits for the healthcare system).
Hence, an unprecedented opportunity now exists to develop and implement an effective public health strategy to prevent CVD, and three major factors might have contributed to this opportunity: (a) more cumulative knowledge and experience in CVD prevention exists now than ever before; 4 (b) major partnerships have been established to support CVD prevention; (c) health professionals increasingly recognise the continuing CVD epidemic, unfavourable recent trends and forecasts of a mounting burden of CVD nationally and worldwide.
Implementation
Despite this opportunity, the implementation of secondary CVD prevention is far from optimal. The European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) crosssectional surveys have evaluated CVD prevention implementation, 9, [18] [19] [20] [21] and results have demonstrated a high prevalence of unhealthy lifestyles, modifiable risk factors and inadequate use of drug therapies to achieve blood pressure and lipid goals. The EUROASPIRE IV 21 showed that, although secondary prevention has improved over time, a large majority of coronary patients still do not achieve guideline goals.
Approximately six months after the event, 48.6% of patients who were smoking at the event were continuing smokers, little or no physical activity was reported, and 37.6% were obese (body mass index 30 kg/m 2 ). Moreover, 42.7% had arterial blood pressure of 140/ 90 mmHg or greater, 80.5% had low-density lipoprotein cholesterol levels of 1.8 mmol/l or greater and 26.8% reported having diabetes. Among diabetes patients, glucose control was relatively poor, with less than half reaching the guideline target of glycated haemoglobin (HbA1c) of less than 7.0 mmol/l. As regards medical treatment the picture was better: 93.8% were on antiplatelet treatment, 82.6% were on beta-blockers; 75.1% were on angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers; and 85.7% were on statins. Finally, of the CVD patients, 50.7% had been advised to participate in a CR programme.
While dissemination alone is not an adequate way of changing practice, it is a prerequisite for guideline implementation. 22 At the moment, although there is no single way to ensure the use of guidelines in practice, multifaceted interventions based on known barriers are most appropriate (Table 3) and undoubtedly include planning, commitment, enthusiasm and resources. Among other things, obstacles embrace lack of market awareness, anger over declining autonomy or power, falling incomes, culture, resources, lack of information, and clinical freedom. 23, 24 Finally, economic implications, administrative concerns as well as the availability of healthcare services across countries should not be ignored.
In partnership with Quintiles, the American Heart Association (AHA) created four premier Get With The Guidelines programmes designed to help hospitals ensure continuous quality improvement in CVD patient care: 25 the programme aims to ensure that eligible patients are initiated on guideline-recommended therapies and receive appropriate counselling prior to hospital discharge. These programmes have an established track record of success, with documented consistently high levels of compliance with the appropriate guidelines. The tools are easy to use and will assist in addressing each patient's needs. 26 Two requirements must be met: 27 first, communication to the public and to policymakers the need and unprecedented opportunity to prevent CVD; second, transformation of the nation's public health structure to provide leadership and to develop and maintain effective partnerships and collaborations to support the needed actions. Essential components are: (a) taking action; (b) strengthening capacity; (c) evaluating impact; (d) advancing policy; and (e) engaging in regional and global partnerships. In these five areas, 22 recommendations and supporting action steps are proposed (Table 4) , and implementation of the plan must assure integration of all components in a coordinated approach that recognises and strengthens the potential linkages among them. The strategy depends on a balanced investment in all available intervention approaches, from policy and environmental changes designed to prevent risk factors to assurance of quality care for the individuals with CVD.
To be explicit and concrete, a detailed description of ideas should be applied to research and more studies on CVD prevention must be designed for implementation guidelines. Although strategies and solutions are stated clearly (Table 4) , a more tangible way of addressing the issue may come from dedicated and validated experiences.
Conclusions
Saving people's lives from acute CVD attacks is not sufficient and interventions should always be followed by prevention. Knowledge about CVD prevention is not a satisfactory basis for public health action, and health service research might, on one hand, address impactful actions and, on the other, tackle insights in a cost-conscious and timely fashion for operational needs. 28 
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